IP Library › Granted Patent US 7,572,447
Granted Patent B2
US 7,572,447 · App. 12/046,795 · Granted Aug 11, 2009

Methods and compositions for selective modulation of vascularization

Assignee: Genentech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,572,447
App. No.
12/046,795
Granted
Aug 11, 2009
Kind
B2
Abstract

The invention provides methods and compositions for modulating vascularization and angiogenesis, including selective modulation of stages of multi-step vascularization and angiogenesis.

Claims (12)

1. A monoclonal antibody that specifically binds to stanniocalcin and that comprises all of the complementarity determining regions (CDRs) of a heavy chain and all of the complementarity determining regions (CDRs) of a light chain from an antibody produced by a hybridoma selected from the group consisting of:

3E10.1F5.1D11 (ATCC Deposit No. PTA-5100); 2F4.2F11.1H12 (ATCC Deposit No. PTA-5103); 1F10.2F12.1E7 (ATCC Deposit No. PTA-5101); 18F1.1E6.1B10 (ATCC Deposit No. PTA-5099); and 12C3.2F3.2D8 (ATCC Deposit No. PTA-5102).

2. The antibody of claim 1 , further comprising a cytotoxic agent.

3. The antibody of claim 1 , further comprising a detectable label.

4. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

5. A hybridoma selected from the group consisting of:

3E10.1F5.1D11 (ATCC Deposit No. PTA-5100); 2F4.2F11.1H12 (ATCC Deposit No. PTA-5103); 1F10.2F12.1E7 (ATCC Deposit No. PTA-5101); 18F1.1E6.1B10 (ATCC Deposit No. PTA-5099); and 12C3.2F3.2D8 (ATCC Deposit No. PTA-5102).

6. A monoclonal antibody produced by a hybridoma selected from the group consisting of:

3E10.1F5.1D11 (ATCC Deposit No. PTA-5100); 2F4.2F11.1H12 (ATCC Deposit No. PTA-5103); 1F10.2F12.1E7 (ATCC Deposit No. PTA-5101); 18F1.1E6.1B10 (ATCC Deposit No. PTA-5099); and 12C3.2F3.2D8 (ATCC Deposit No. PTA-5102).

7. The antibody of claim 6 , further comprising a cytotoxic agent.

8. The antibody of claim 6 , further comprising a detectable label.

9. A pharmaceutical composition comprising the antibody of claim 6 and a pharmaceutically acceptable carrier.

Continuity (3)
Continuation 1082407500 · Apr 14, 2004
Provisional Application 6046322600 · Apr 16, 2003
Related Publication 20080241159A1 · Oct 2, 2008